In any given week, media headlines publicize the benefits of a new “breakthrough” cancer drug, with patients and clinicians subsequently advocating for its use. Governments, which face the difficult task of deciding how best to allocate limited public resources, must at the same time balance ongoing commitments to provide optimal health care for Canadians and to ensure value for money and the sustainability of the Canadian health care system.
Established by the provincial and territorial ministries of health, the pan-Canadian Oncology Drug Review (pcodr) program operating within the Canadian Agency for Drugs and Technologies in Health (cadth) is designed to bring consistency and clarity to the assessment of cancer drugs by looking at clinical and economic evidence, by taking into consideration clinician and patient perspectives, and by using that information to make recommendations to the participating jurisdictions to guide their drug funding decisions.
Read more here.
No comments:
Post a Comment